FSD Pharma CEO, Dr. Raza Bokhari, Discusses 2020 Goals with The Stock Day Podcast

About this update from Quantum Biopharma Ltd. Subordinate Voting Shares Class B

[{"type":"text","content":"FSD Pharma CEO, Dr. Raza Bokhari, Discusses 2020 Goals with The Stock Day PodcastPhoenix, Arizona--(Newsfile Corp. - February 11, 2020) - The Stock Day Podcast welcomed FSD Pharma (NASDAQ: HUGE) (the Company\"), a specialty biotech pharmaceutical R&D company focused on developing over time a robust pipeline of FDA-approved synthetic compounds targeting the endocannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system. CEO of the Company, Dr. Raza Bokhari, joined Stock Day host Everett Jolly. \"What can everyone expect from your company in 2020 and beyond?\", asked Jolly to begin the interview. \"2020 has been a great start for us. We began trading on the NASDAQ on January 9th,\" shared Dr. Bokhari. \"We have a huge opportunity and responsibility ahead of us,\" said Dr. Bokhari. \"The company now has a strategic advantage; We have become one of twelve Canadian domiciled companies in cannabis-related business that are listed on either the NASDAQ or NYSE,\" said Dr. Bokhari. \"The primary thrust of our focus is to advance clinical research and development through FDA approved trials, and hopefully to bring to market some commercial applications of synthetic compounds including cannabinoid compounds that target the CB2 receptors of the human body,\" shared Dr. Bokhari. He then shared that the Company is confident that they will initiate human safety and tolerability studies for ultra micronized-PEA before the end of the current quarter, and will also perform animal safety and pharmacology studies. \"Hopefully, this time next year we will have some positive results to share, and then hopefully we can secure an IND with the FDA and start Phase II trials looking into the applications of ultra micronized-PEA,\" said Dr. Bokhari. The conversation then turned to the sales license for the Company's grow facility. \"We are a licensed grower and producer of medicinal grade cannabis in Canada,\" explained Dr. Bokhari. \"Our sales are limited to Canadian prescription-based consumers,\" he added. \"We have also applied to expand our license to also do sales of CBD oil and a CBD/THC combination oil,\" shared Dr. Bokhari. The Company is also in the process of bringing gel caps and extended release tablets to market in Canada throu...

More updates from Quantum Biopharma Ltd. Subordinate Voting Shares Class B